Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Colgate-Palmolive (NYSE:CL) Price Target Raised to $106.00

AI-generated analysis

πŸ“ˆ UBS Group raised Colgate-Palmolive's price target to $106.00 from $100.00 while maintaining a buy rating.

πŸ“Š The company beat Q2 earnings estimates with $0.97 EPS versus the consensus of $0.94.

πŸ’° Revenue grew 8.4% year-over-year to reach $5.32 billion, surpassing analyst expectations of $5.22 billion.

πŸ“‰ Bank of America lowered its price target to $102.00 despite maintaining a buy rating on the stock.

πŸ’΅ A quarterly dividend of $0.53 per share will be paid on August 14th with an ex-dividend date of July 20th.

🏦 HighPoint Advisor Group LLC increased its stake by 0.7% to own 15,877 shares valued at $1.255 million.

πŸ“ˆ Clear Harbor Asset Management LLC boosted its holdings by 2.6% in the fourth quarter.

πŸ” The stock holds a consensus rating of Moderate Buy with an average price target of $97.41 from twelve analysts.

🏭 Colgate-Palmolive operates globally in oral care, personal care, home care, and pet nutrition categories.

πŸ“‰ The company reported a return on equity of 386.76% and a net margin of 10.04% for the quarter.

Bullish Signals
  • UBS Group raised its price target to $106.00, signaling confidence in the stock's valuation.
  • The company beat quarterly earnings estimates by $0.03 per share, demonstrating operational strength.
  • Revenue increased by 8.4% year-over-year to $5.32 billion, exceeding analyst forecasts of $5.22 billion.
  • Analyst consensus remains a Moderate Buy with twelve buy ratings compared to seven hold ratings.
  • The company maintains a healthy dividend yield of 2.3% with an annualized payout of $2.12 per share.
  • Institutional investors like HighPoint Advisor Group LLC and Clear Harbor Asset Management LLC increased their positions.
Risk Factors
  • Bank of America decreased its price target from $105.00 to $102.00, indicating some caution on valuation.
  • Sanford C. Bernstein initiated coverage with a neutral market perform rating and a lower $96.00 price target.
Full Analysis
UBS Group raised its price target for Colgate-Palmolive (NYSE:CL) to $106.00 from $100.00, maintaining a buy rating. This follows a series of analyst actions including Piper Sandler lifting its target to $96.00 with an overweight rating and Goldman Sachs restating a buy. Conversely, Bank of America lowered its target to $102.00, while Sanford C. Bernstein initiated coverage with a market perform rating at $96.00. The consensus remains a Moderate Buy with a price target of $97.41 based on twelve buy and seven hold ratings. Colgate-Palmolive reported strong financial results for the quarter ending May 1st, posting $0.97 in earnings per share against a consensus estimate of $0.94. Revenue reached $5.32 billion, exceeding analyst expectations of $5.22 billion and representing an 8.4% year-over-year increase. The company demonstrated robust profitability with a return on equity of 386.76% and a net margin of 10.04%, while the prior year quarter saw earnings of $0.91 per share. The company announced a quarterly dividend to be paid on August 14th for shareholders of record on July 20th, offering $0.53 per share. This translates to an annualized dividend of $2.12 with a yield of 2.3% and a payout ratio of 82.49%. Institutional investors have also increased their stakes, with HighPoint Advisor Group LLC raising its position by 0.7% and Clear Harbor Asset Management LLC lifting holdings by 2.6% in the fourth quarter.